Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473242 | 1.00 | HDAC3 (0.39) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| SCHEMBL6472670 | 0.76 | NPSR1 (0.46) | CES2CES1KDM4EATMALDH1A1 | |
| SCHEMBL7562791 | 0.72 | FFAR3 (0.33) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| SCHEMBL7562797 | 0.72 | FFAR3 (0.33) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| SCHEMBL28963609 | 0.70 | — | — | |
| SCHEMBL4833334 | 0.69 | HDAC3 (0.48) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| SCHEMBL3939667 | 0.69 | — | — | |
| SCHEMBL3939673 | 0.69 | — | — | |
| SCHEMBL195384 | 0.67 | — | — | |
| SCHEMBL2152750 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921777-B2 | Heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-26 | — | — | US | disclosed |
| US-20030012803-A1 | Novel heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-01-16 | — | — | US | disclosed |
| US-6444709-B1 | SKIN DISORDERS; ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2002-09-03 | — | — | US | disclosed |
| EP-0986537-B1 | NOVEL HETEROETHYNYLENE COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RES & DEV (FR) | 2002-08-07 | — | — | EP | disclosed |
| EP-0986537-A2 | NOVEL HETEROETHYNYLENE COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | Galderma Research & Development, S.N.C. (FR) | 2000-03-22 | — | — | EP | disclosed |
| WO-1999050239-A2 | NOVEL HETEROETHYNYLENE COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030012803-A1 | Novel heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | TYR, CYP1B1, MITF | HDAC3 2582/4885HDAC1 1930/4885HDAC2 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.